SCHEMBL8259609

SCHEMBL8259609

Fc1cc(CN2CCCC2)ccc1N1CCNCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
HTT P42858 1/20 0.58
CXCR4 P61073 8/20 0.50
HRH3 Q9Y5N1 2/20 0.50
MEN1 O00255 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
ADRA2C P18825 1/20 0.50
CCR2 P41597 1/20 0.50
CXCL12 P48061 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28129037 0.94 ALDH1A1 (0.54) ALDH1A1HTTCXCR4HRH3MEN1
SCHEMBL8251024 0.87 PIK3CA (0.47) ALDH1A1HTTHRH3SMN1; SMN2KDM4E
SCHEMBL12828065 0.81 HTR6 (0.46) ALDH1A1SMN1; SMN2MAPTLMNAGAA
SCHEMBL8250737 0.80 HTR6 (0.45) ALDH1A1SMN1; SMN2MAPTLMNAGAA
SCHEMBL18052714 0.80 HTR6 (0.50) ALDH1A1HRH3MAPTKCNH2HTR6
SCHEMBL4939123 0.78 ALDH1A1 (0.56) ALDH1A1HTTHRH3ADRA2CSMN1; SMN2
SCHEMBL29756449 0.78 ALDH1A1 (0.69) ALDH1A1HTTCXCR4HRH3MEN1
SCHEMBL2921989 0.78 ALDH1A1 (0.69) ALDH1A1HTTCXCR4HRH3MEN1
SCHEMBL31583816 0.78 CRBN (0.50) ALDH1A1SMN1; SMN2MAPTLMNAGAA
SCHEMBL5023862 0.78 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2MAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 ALDH1A1 591/4885HTT 168/4885CXCR4 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.